PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC. Kim I, Choi SH, Lee SY, Yoo SS, et al. Anticancer Res 2024;44:4505-4516.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim I, Choi SH, Lee SY, Yoo SS, et al. PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC. Anticancer Res 2024;44:4505-4516.
PMID: 39348962